

**Abstract Submission No. : IL-9004**

## **A Novel Therapeutic Strategy of ADPKD**

YOSHITAKA ISAKA

*Osaka University Graduate School of Medicine, Japan*

Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. Tolvaptan is a highly selective vasopressin V2 receptor antagonist indicated for use in patients with ADPKD. In the large phase III TEMPO 3:4 trial in adults with ADPKD, 3 years' treatment with oral tolvaptan significantly reduced growth in total kidney volume and slowed renal function decline relative to placebo. Subsequent clinical studies also showed the effectiveness of tolvaptan in patients with ADPKD. Here, I would like to discuss the therapeutic strategies for ADPKD patients.